TABLE 1.
Demographic and clinical chacteristics of patients in the two cohorts.
| Variable | Younger adult cohort (n = 161) | Elderly cohort (n = 143) | p-value |
|---|---|---|---|
| Sex | — | — | 0.001 |
| Male (n [%]) | 96 (59.6) | 110 (76.9) | — |
| Female (n [%]) | 65 (40.4) | 33 (23.1) | — |
| Age (y) | 43 ± 12 | 72 ± 8 | <0.001 |
| Underlying diseases | — | — | — |
| Leukemia (no. [%]) | 44 (27.3) | 9 (6.3) | — |
| Hypertension (no. [%]) | 40 (24.8) | 59 (41.3) | — |
| Diabetes mellitus (no. [%]) | 23 (14.3) | 44 (30.8) | — |
| Coronary heart disease (no. [%]) | 2 (1.2) | 18 (12.6) | — |
| Kidney disease (no. [%]) | 69 (42.9) | 53 (37.1) | — |
| Pneumonia (no. [%]) | 97 (60.2) | 113 (79.0) | — |
| Fungus category | — | ||
| Aspergillus (no. [%]) | 29 (18.0) | 36 (25.2) | — |
| Saccharomycetes (no. [%]) | 14 (8.7) | 21 (14.7) | — |
| Monilia (no. [%]) | 26 (16.1) | 33 (23.1) | — |
| Unidentified fungi (no. [%]) | 30 (18.6) | 27 (18.9) | — |
| Others (no. [%]) | 5 (3.1) | 1 (0.7) | — |
| Negative (no. [%]) | 58 (36.0) | 34 (23.8) | — |
| Route of administration | — | — | 0.115 |
| Intravenous (n [%]) | 130 (80.7) | 125 (87.4) | — |
| Oral (n [%]) | 31 (19.3) | 18 (12.6) | — |
| VCZ dose (mg/kg/dose) | 3.6 ± 0.9 | 3.4 ± 0.9 | 0.023 |
| Use of PPI | 84 (52.2) | 80 (55.9) | 0.510 |
A patient may have several underlying diseases or fungus categories. Abbreviations: PPI, proton-pump inhibitor.